Flagship Biosciences provides pharmaceutical and biotech companies with spatial biology and biomarker insights, AI-driven technology, and scientific consultation for drug development and diagnostics.
Boaz focuses on spatial technologies that combine digitized histopathology with proteomic and genomic biomarker assessment. He founded Intersect Diagnostics and served as Vice President of Molecular Pathology at Cancer Genetics, Inc.
Dr. Young specializes in diagnosing hematologic cancers and classifying blood cancers using molecular and genetic profiling. Dr. Young serves as Director of Hematopathology and Vice Chair of Research.
The professional has over 18 years of immunology and oncology research experience, including 12 years focused on cancer therapeutics, biomarker discovery, drug design, and target validation.
Flagship Biosciences is a CLIA-certified, CAP-accredited spatial biology and biomarker services company. Since 2009, it has provided AI-powered analysis and expert consultation for drug development and diagnostics.
